Lumida
/NKTR
⌘K
Nektar Therapeutics

Nektar Therapeutics

NKTR
$68.26USD↑+1.80%+1.21 today

MARKET CAP

2.3B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$66 – $69

52W RANGE

$21
$109

AI Summary

Stalk
StalkMedium

NKTR is in Stage 2 with a corrective reset showing higher highs and higher lows above repaired EMA support. Bullish medium-term bias is reinforced by a Bullish Pivot Point and continuation structure, but short-term timing remains neutral as price pulls back into rising EMAs and the 50 DMA. Execution posture is to stalk and await acceptance at the EMA/50 DMA support zone before engaging on the long side.

  • ↑Phase II RESPEG trials demonstrate durable and deepening responses
  • ↑Ended Q1 2026 with >$1 B cash, funding Phase III development
  • ↓Q1 net loss of $44.9 M far exceeds $10.5 M revenues
Full analysis →
Insider Trades46 trades
Date↓SideTicker↕Insider↕Role↕Shares↕Price↕Mkt Cap↕52W High↕52W Low↕Value↕% Chg↕Rule↕AI View↕
Jun 30, 2026SellNKTRJonathan ZalevskyChief R&D Officer5,681$70.00$2.3B-37.38%+224.74%$397.7K-36.80%—Sell Now
Jun 16, 2026SellNKTRHoward W RobinPresident & CEO20,000$60.75$2.3B-37.38%+224.74%$1.2M-7.42%—Sell Now
Jun 15, 2026SellNKTRJonathan ZalevskyChief R&D Officer5,538$60.71$2.3B-37.38%+224.74%$336.2K-26.40%—Sell Now
May 19, 2026SellNKTRJonathan ZalevskyChief R&D Officer199$65.51$2.3B-37.38%+224.74%$13.0K-0.94%—Sell Now
May 19, 2026SellNKTRHoward W RobinPresident & CEO444$65.51$2.3B-37.38%+224.74%$29.1K-0.59%—Sell Now
Feb 18, 2026SellNKTRJonathan ZalevskyChief R&D Officer180$73.00$2.3B-37.38%+224.74%$13.1K-0.84%—Sell Now
Feb 18, 2026SellNKTRHoward W RobinPresident & CEO423$73.00$2.3B-37.38%+224.74%$30.9K-0.56%—Sell Now
Jan 20, 2026SellNKTRJonathan ZalevskyChief R&D Officer3,867$35.67$2.3B-37.38%+224.74%$137.9K-15.33%—Sell Now
Nov 25, 2025SellNKTRMark Andrew WilsonChief Legal Officer630$54.28$2.3B-37.38%+224.74%$34.2K-2.46%—Sell Now
Nov 25, 2025SellNKTRJonathan ZalevskyChief R&D Officer1,157$54.28$2.3B-37.38%+224.74%$62.8K-4.65%—Sell Now
Nov 25, 2025SellNKTRHoward W RobinPresident & CEO2,207$54.28$2.3B-37.38%+224.74%$119.8K-3.22%—Sell Now
Sep 9, 2025SellNKTRHoward W RobinPresident & CEO6,666$46.69$2.3B-37.38%+224.74%$311.2K-3.13%—Sell Now
Sep 4, 2025SellNKTRJonathan ZalevskyChief R&D Officer1,721$33.52$2.3B-37.38%+224.74%$57.7K-2.35%—Sell Now
Sep 4, 2025SellNKTRHoward W RobinPresident & CEO11,832$36.42$2.3B-37.38%+224.74%$431.0K-2.68%—Sell Now
Sep 2, 2025SellNKTRJonathan ZalevskyChief R&D Officer485$30.10$2.3B-37.38%+224.74%$14.6K-2.47%—Sell Now
Sep 2, 2025SellNKTRHoward W RobinPresident & CEO1,500$30.16$2.3B-37.38%+224.74%$45.2K-2.16%—Sell Now
Aug 19, 2025SellNKTRMark Andrew WilsonChief Legal Officer676$26.59$2.3B-37.38%+224.74%$18.0K-1.58%—Sell Now
Aug 19, 2025SellNKTRJonathan ZalevskyChief R&D Officer725$26.59$2.3B-37.38%+224.74%$19.3K-1.96%—Sell Now
Aug 19, 2025SellNKTRHoward W RobinPresident & CEO1,573$26.59$2.3B-37.38%+224.74%$41.8K-1.00%—Sell Now
May 19, 2025SellNKTRMark Andrew WilsonChief Legal Officer9,996$0.67$2.3B-37.38%+224.74%$6.7K-3.08%—Sell Now
May 19, 2025SellNKTRJonathan ZalevskyChief R&D Officer10,712$0.67$2.3B-37.38%+224.74%$7.2K-3.38%—Sell Now
May 19, 2025SellNKTRHoward W RobinPresident & CEO23,208$0.67$2.3B-37.38%+224.74%$15.5K-2.14%—Sell Now
Feb 19, 2025SellNKTRJonathan ZalevskyChief R&D Officer10,300$1.01$2.3B-37.38%+224.74%$10.4K-3.15%—Sell Now
Feb 19, 2025SellNKTRMark Andrew WilsonChief Legal Officer11,040$1.01$2.3B-37.38%+224.74%$11.2K-3.29%—Sell Now
Feb 19, 2025SellNKTRHoward W RobinPresident & CEO23,774$1.01$2.3B-37.38%+224.74%$24.0K-2.14%—Sell Now
Dec 23, 2024SellNKTRMark Andrew WilsonChief Legal Officer49,962$0.90$2.3B-37.38%+224.74%$44.8K-6.78%—Sell Now
Dec 19, 2024SellNKTRJonathan ZalevskyChief R&D Officer51,115$0.94$2.3B-37.38%+224.74%$48.0K-13.52%—Sell Now
Dec 17, 2024SellNKTRHoward W RobinPresident & CEO132,030$1.00$2.3B-37.38%+224.74%$131.6K-5.41%—Sell Now
Nov 19, 2024SellNKTRMark Andrew WilsonChief Legal Officer6,407$1.01$2.3B-37.38%+224.74%$6.5K-2.84%—Sell Now
Nov 19, 2024SellNKTRJonathan ZalevskyChief R&D Officer7,785$1.01$2.3B-37.38%+224.74%$7.9K-3.10%—Sell Now
Nov 19, 2024SellNKTRHoward W RobinPresident & CEO16,278$1.01$2.3B-37.38%+224.74%$16.4K-1.92%—Sell Now
Aug 19, 2024SellNKTRMark Andrew WilsonChief Legal Officer5,651$1.28$2.3B-37.38%+224.74%$7.2K-2.45%—Sell Now
Aug 19, 2024SellNKTRJonathan ZalevskyChief R&D Officer6,866$1.28$2.3B-37.38%+224.74%$8.8K-2.66%—Sell Now
Aug 19, 2024SellNKTRHoward W RobinPresident & CEO14,881$1.28$2.3B-37.38%+224.74%$19.0K-1.72%—Sell Now
May 17, 2024SellNKTRMark Andrew WilsonChief Legal Officer6,260$1.75$2.3B-37.38%+224.74%$11.0K-2.64%—Sell Now
May 17, 2024SellNKTRJonathan ZalevskyChief R&D Officer7,355$1.75$2.3B-37.38%+224.74%$12.9K-2.78%—Sell Now
May 17, 2024SellNKTRHoward W RobinPresident & CEO16,650$1.75$2.3B-37.38%+224.74%$29.1K-1.89%—Sell Now
Feb 20, 2024SellNKTRMark Andrew WilsonChief Legal Officer7,606$0.68$2.3B-37.38%+224.74%$5.2K-3.11%—Sell Now
Feb 20, 2024SellNKTRJonathan ZalevskyChief R&D Officer9,014$0.68$2.3B-37.38%+224.74%$6.1K-3.29%—Sell Now
Feb 20, 2024SellNKTRHoward W RobinPresident & CEO20,033$0.68$2.3B-37.38%+224.74%$13.6K-2.23%—Sell Now
Nov 17, 2023SellNKTRMark Andrew WilsonChief Legal Officer7,179$0.49$2.3B-37.38%+224.74%$3.5K-2.86%—Sell Now
Nov 17, 2023SellNKTRJonathan ZalevskyChief R&D Officer9,646$0.49$2.3B-37.38%+224.74%$4.7K-3.40%—Sell Now
Nov 17, 2023SellNKTRHoward W RobinPresident & CEO19,877$0.49$2.3B-37.38%+224.74%$9.7K-2.16%—Sell Now
Aug 16, 2023SellNKTRMark Andrew WilsonChief Legal Officer7,221$0.78$2.3B-37.38%+224.74%$5.6K-2.80%—Sell Now
Aug 16, 2023SellNKTRJonathan ZalevskyChief R&D Officer9,703$0.78$2.3B-37.38%+224.74%$7.6K-3.31%—Sell Now
Aug 16, 2023SellNKTRHoward W RobinPresident & CEO19,998$0.78$2.3B-37.38%+224.74%$15.6K-2.13%—Sell Now